Jason M. Schenkel, M.D., Ph.D.
Department of Laboratory Medicine, Division of Pathology-Lab Medicine Div
About Dr. Jason M. Schenkel
My overarching goal is to be a physician scientist at a major academic medical institution where I will run a basic science research laboratory (80-90% effort) as well as practice transfusion medicine/blood banking (10-20% of the time). My efforts will be focused on obtaining grant funding to support the efforts within the laboratory, mentoring students, residents and fellows in the contexts of the laboratory and hospital, and disseminating our laboratory findings at conferences and by publishing papers.
My longitudinal research efforts are focused on understanding the dynamics of the immune response to cancer. Specifically, I am interested in determining which immune cells are present within the tumor microenvironment, when and how they trafficked to tumors, where they are localized, and what functions these different leukocyte populations have over the course of tumorigenesis. I will approach these questions using newer technologies or innovative experimental techniques, including parabiosis, non-immunosuppresive bone marrow transplantation, proximity labeling to identify cell-cell interactions and single cell RNAseq to examine downstream pathways that are engaged in different cell types. Invariably, findings from these studies will not only further our understanding of the tumor microenvironment, but will also likely lead to new methodologies or approaches to treating cancer.
Present Title & Affiliation
Primary Appointment
Assistant Professor (Joint appointment), Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX
Assistant Professor (Joint appointment), Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX
Assistant Professor, Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Assistant Professor, Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Assistant Professor (Joint appointment), Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX
Assistant Professor (Joint appointment), Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2014 | University of Minnesota, Minneapolis, Minnesota, US, Immunology and Cancer Biology, Ph.D. in Immunology |
| 2016 | University of Minnesota, Minneapolis, Minnesota, US, MD |
| 2008 | Northwestern University, Evanston, Illinois, US, BS in Human Communication Sciences |
Postgraduate Training
| 2019-2020 | Clinical Fellowship, Transfusion Medicine, Harvard Medical School, Boston, Massachusetts |
| 2018-2022 | Research Fellowship, Massachusetts Institute of Technology, Cambridge, Massachusetts |
| 2016-2019 | Clinical Residency, Clinical Pathology, Brigham and Women's Hospital, Boston, Massachusetts |
Licenses & Certifications
| 2023 | American Board of Pathology - Transfusion Medicine |
| 2022 | Texas Medical License |
| 2021 | American Board of Pathology - Clinical Pathology |
Experience & Service
Intramural Institutional Committee Activities
Committee Member, Sarah Ghalayini Candidacy Examination Committee, The University of Texas MD Anderson Cancer Center, 2026
Committee Member, Shruthi Kannan Candidacy Examination Committee, The University of Texas MD Anderson Cancer Center, 2026
Committee Member, Tala Noun Candidacy Examination Committee, The University of Texas MD Anderson Cancer Center, 2025
Chair, Annette Wu Candidacy Examination Committee, The University of Texas MD Anderson Cancer Center, 2025
Committee Member, Ahmed Shatta Candidacy Examination Committee, The University of Texas MD Anderson Cancer Center, 2025
Committee Member, Joshua Wan Thesis Committee, The University of Texas MD Anderson Cancer Center, 2025 - Present
Member, DPLM Research and Development Committee, The University of Texas MD Anderson Cancer Center, 2025 - Present
Committee Member, Brian Koehler Thesis Committee, The University of Texas MD Anderson Cancer Center, 2025 - Present
Committee Member, Aaron Bickert Thesis Committee, The University of Texas MD Anderson Cancer Center, 2025 - Present
Committee Member, Zohra Nizami Thesis Committee, The University of Texas MD Anderson Cancer Center, 2025 - Present
Committee Member, Alexandria Williams Thesis Committee, The University of Texas MD Anderson Cancer Center, 2025 - Present
Committee Member, Yue Xuan Candidacy Examination Committee, The University of Texas MD Anderson Cancer Center, 2025
Committee Member, Candise Tse Thesis Committee, The University of Texas MD Anderson Cancer Center, 2025 - Present
Committee Member, Nourhan Ahmed Thesis Committee, The University of Texas MD Anderson Cancer Center, 2025 - Present
Committee Member, Jiarui Li Thesis Committee, The University of Texas MD Anderson Cancer Center, 2025 - Present
Committee Member, Yang Zhou Thesis Committee, The University of Texas MD Anderson Cancer Center, 2025 - Present
Chair, Charles Inaku Thesis Committee, The University of Texas MD Anderson Cancer Center, 2025 - Present
Committee Member, Ricardo Gonzalez Delgado Candidacy Examination Committee, The University of Texas MD Anderson Cancer Center, 2025
Committee Member, Timothy Bi Candidacy Examination Committee, The University of Texas MD Anderson Cancer Center, 2025
Committee Member, Andres Lopez Rivas Thesis Committee, The University of Texas MD Anderson Cancer Center, 2025 - Present
Chair, Samuel Andrewes Candidacy Examination Committee, The University of Texas MD Anderson Cancer Center, 2025
Committee Member, Minyue Chen Candidacy Examination Committee, The University of Texas MD Anderson Cancer Center, 2024
Chair, David Won Candidacy Examination Committee, The University of Texas MD Anderson Cancer Center, 2024
Co-Director, UT Houston/MDACC MSTP Executive Committee, The University of Texas MD Anderson Cancer Center/UT Houston, 2024 - Present
Committee Member, Annette Wu Thesis Committee, The University of Texas MD Anderson Cancer Center, 2024 - Present
Committee Member, Ahmed Shatta Thesis Committee, The University of Texas MD Anderson Cancer Center, 2024 - Present
Committee Member, Wei-Chieh Yu Thesis Committee, The University of Texas MD Anderson Cancer Center, 2024 - Present
Committee Member, Trisha Wathan Committee, The University of Texas MD Anderson Cancer Center, 2024 - Present
Committee Member, UT Houston/MDACC GSBS Immunology Steering Committee, The University of Texas MD Anderson Cancer Center/UT Houston, 2024 - Present
Chair, Thierry Iraguha Thesis Committee, The University of Texas MD Anderson Cancer Center, 2024 - Present
Committee Member, Akash Boda Thesis Committee, The University of Texas MD Anderson Cancer Center, 2024 - 2024
Committee Member, Morgan Riba Candidacy Examination Committee, The University of Texas MD Anderson Cancer Center, 2024
Committee Member, Guillaume Trusz Candidacy Examination Committee, The University of Texas MD Anderson Cancer Center, 2024
Committee Member, Sarah Schneider Candidacy Examination Committee, The University of Texas MD Anderson Cancer Center, 2024
Committee Member, Shucheng Miao Candidacy Examination Committee, The University of Texas MD Anderson Cancer Center, 2024
Member, Srinath Lakshmivenkatesh Thesis Committee, The University of Texas MD Anderson Cancer Center, 2023 - Present
Member, Ruparoshni Jayabalan Thesis Committee, The University of Texas MD Anderson Cancer Center, 2023 - Present
Committee Member, Faculty Wellness Working Group, The University of Texas MD Anderson Cancer Center, 2023 - Present
Member, Mitheera V Thesis Committee, The University of Texas MD Anderson Cancer Center, 2023 - Present
Member, Samuel Andrewes Thesis Committee, The University of Texas MD Anderson Cancer Center, 2023 - Present
Member, David Won Thesis Committee, The University of Texas MD Anderson Cancer Center, 2023 - Present
Committee Member, Samuel Andrewes Thesis Committee, The University of Texas MD Anderson Cancer Center, 2023 - Present
Committee Member, Laboratory Medicine Chair search Advisory Committee, The University of Texas MD Anderson Cancer Center, 2023 - Present
Committee Member, Strategic Operational Priority Working Group, The University of Texas MD Anderson Cancer Center, 2023 - Present
Extramural Institutional Committee Activities
Committee Member, Lihong Xu Thesis Committee, Baylor College, 2025 - Present
Committee Member, Longling Shui Thesis Committee, Cold Spring Harbor Laboratory, 2025 - Present
Committee Member, Advanced Scholars Committee, The University of Texas MD Anderson Cancer Center, 2025 - Present
Committee Member, Amanda Xia Thesis Committee, Baylor College, 2024 - Present
Honors & Awards
| 2026 - Present | Young Physician Scientist Award, American Society for Clinical Investigation |
| 2026 - Present | Early Career Investigator Travel Awards, Keystone Symposia |
| 2024 - Present | Highly Cited Researchers List - Web of Science Group |
| 2023 - Present | Highly Cited Researchers List - Web of Science Group |
| 2022 - Present | Highly Cited Researchers List - Web of Science Group |
| 2021 - Present | Highly Cited Researchers List - Web of Science Group |
| 2020 - Present | Highly Cited Researchers List - Web of Science Group |
| 2019 - 2023 | Highly Cited Researchers List - Web of Science Group |
| 2019 | Paul E. Strandjord Young Investigator Award for ACLPS 2019 |
| 2015 | Paul E. Strandjord Young Investigator Award for ACLPS 2015 |
| 2015 | University of Minnesota Best Dissertation Award: Biology and Medical Sciences 2014-2015 |
| 2015 | Venenziele-Steer Award |
| 2015 | MICaB Travel Award |
| 2015 | NIAID Scholarship for travel to Keystone Symposia-Viral Immunity |
| 2015 | J. Jacob Kaplan Award |
| 2014 | Beatrice Z. Milne and Theodore Brandenburg Award |
| 2013 | Chen MICaB Outstanding Graduate Student Award |
| 2012 | Bill and Melinda Gates Foundation Scholarship for travel to Keystone Symposia, Immunological Mechanisms of Vaccination |
| 2011 | American Association of Immunologists Travel Award |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2026. Watching the clock: Tracking and perturbing leukocyte migration into tumors to potentiate anti-tumor immunity. Invited. MD Anderson - Princess Margaret Cancer Centre Joint Research Symposium. Houston, Texas, US.
- 2025. It's all about time: Tools for tracking immune cell migration from blood to tissue. Invited. FY25 IOTOX Research Seminar Series. Houston, Texas, US.
- 2025. Buried in time: Tracking leukocytes in cancer and inflammation. Invited. MCO Distinguished Scientist Seminar Series. Houston, Texas, US.
- 2024. Stopping the surveyors OR Inflammation mediated leukocyte paralysis. Invited. Calabresi Scholar and Physician-Scientist Symposium. Houston, Texas, US.
- 2024. Inflammation says stop, but we say go! OR Systemic leukocyte migration paralysis after acute inflammatory insults. Invited. Division of Pathology and Laboratory Medicine Grand Rounds. Houston, Texas, US.
- 2024. Entering the 4th dimension: tracking leukocyte migration in cancer and inflammation. Invited. SCT Immunotherapy Team Seminar Series. Houston, Texas, US.
- 2024. Life advice and leukocytes. Invited. UT Houston/MDACC MSTP Topics Seminar Series. Houston, Texas, US.
- 2024. Welcome to the 4th dimension: tracking leukocyte migration in homeostasis and inflammation. Invited. Gulf Coast Consortia (GCC) Immunology Conference. Houston, Texas, US.
- 2024. Conquering the 4th dimension OR how I learned to stop worrying and track leukocyte migration into tumors. Invited. Cancer Biology Seminar Series. Houston, Texas, US.
- 2023. Welcome to the 4th dimension: tracking leukocyte migration to tissues and tumors. Invited. Allison Institute Seminar Series. Houston, Texas, US.
- 2023. Seed versus soil orHow does tumor location vs tumor origin affect the immune response. Invited. Thoracic Tissue and Data Projects Meeting. Houston, Texas, US.
- 2023. Continual Recruitment of Systemic Tregs to Tumors Mediate Local Immunosuppression. Invited. The Department of Hematopoietic Biology and Malignancy Scientific Seminar. Houston, Texas, US.
- 2023. Continual Recruitment of Systemic Tregs to Tumors Mediate Local Immunosuppression. Invited. Research Exchange Lecture Series. Houston, Texas, US.
- 2022. Continual Recruitment of Systemic Tregs to Tumors Mediate Local Immunosuppression. Invited. Division of Pathology and Laboratory Medicine Grand Rounds. Houston, Texas, US.
- 2022. Continual Recruitment of Systemic Tregs to Tumors Mediate Local Immunosuppression. Invited. CCSG GI Program Seminar Series. Houston, Texas, US.
National Presentations
- 2026. Exploring TRM phenotypes and functions across disease. Invited. Washington, District of Columbia, US.
- 2026. Hickory dickory dock: Tracking leukocytes around the clock. Invited. Dartmouth Immunology Retreat. Lebanon, New Hampshire, US.
- 2026. Winding back the clock OR defining leukocyte dynamics in cancer and inflammation. Invited. Stanford, California, US.
- 2025. Seeing the 4th dimension OR how I learned to stop worrying and track leukocyte migration into tumors. Invited, US.
- 2025. Winding back the clock – tracking T cell migration in cancer and inflammation. Invited, US.
- 2024. Welcome to the 4th dimension: tracking leukocyte migration to tumors. Invited. Hanover, New Hampshire, US.
- 2023. Continual Recruitment of Systemic Tregs to Tumors Mediate Local Immunosuppression. Invited. New York City, New York, US.
International Presentations
- 2026. Inflammatory stress drives intravascular myeloid cell accumulation in adrenal gland blood vessels. Invited. Inflammation Resolution: Emerging Concepts, Mechanisms and Disease Insights. Silverthorne, US.
- 2023. Continual Recruitment of Systemic Tregs to Tumors Mediate Local Immunosuppression. Invited. Keystone Symposia: Cancer Immunotherapy: Mechanisms of Response versus Resistance, US.
Grant & Contract Support
| Date: | 2027 - 2031 |
| Title: | Therapeutically Targeting the Tumor-Draining Lymph Node to Improve PD-1 Cancer Immunotherapy |
| Funding Source: | ACS |
| Role: | PI |
| ID: | FP00030730 |
| Date: | 2026 - 2031 |
| Title: | Temporally Mapping How Inflammation Drives Innate Immune Repositioning in the Body |
| Funding Source: | NIGMS |
| Role: | PI |
| ID: | 1 R35 GM 168168 - 01 |
| Date: | 2026 - 2030 |
| Title: | Preventing Cardiotoxicity in AYA Sarcoma Survivors using Tirzepatide: A Phase II single Arm, Feasibility Study |
| Funding Source: | CPRIT |
| Role: | Co-I |
| ID: | RP 270129 |
| Date: | 2026 - 2029 |
| Title: | Plasma Membrane Lipid Homeostasis as a Targetable Regulator of T-Cell Dysfunction in Pancreatic Cancer |
| Funding Source: | CPRIT |
| Role: | Co-I |
| ID: | FP00030185 |
| Date: | 2026 - 2029 |
| Title: | Improving PD-1-Based Immunotherapy by Developing Strategies to Mobilize Tumor Antigen-Specific CD8 T Cells From Lymph Nodes |
| Funding Source: | CPRIT |
| Role: | PI |
| ID: | RP 270187 |
| Date: | 2026 - Present |
| Title: | Disentangling Melanoma and Immune Cell Secreted Factors to Identify New Therapeutic Vulnerabilities |
| Funding Source: | ACS |
| Role: | PI |
| ID: | FP00028711 |
| Date: | 2026 - Present |
| Title: | Harnessing Precision Proton Therapy to Enhance Cancer Outcomes: From Mechanistic Insight to Clinical Translation |
| Funding Source: | NCI |
| Role: | Co-I |
| ID: | FP00027247 |
| Date: | 2026 - 2030 |
| Title: | Harnessing membrane dynamics to enhance antitumor immunity |
| Funding Source: | V Foundation for Cancer Research |
| Role: | Co-I |
| ID: | FP00029637 |
| Date: | 2026 - 2031 |
| Title: | The Future of Cancer Research: Training Program for Basic and Translational Scientists |
| Funding Source: | CPRIT |
| Role: | Co-I |
| ID: | RP 260817 |
| Date: | 2026 - Present |
| Title: | Identifying Novel Immunotherapy Targets by Interrogating Tumor-immune Secretomes |
| Funding Source: | Robert J Kleberg Jr and Helen C Kleberg Foundation |
| Role: | PI |
| ID: | FP00028126 |
| Date: | 2026 - 2031 |
| Title: | Mechanisms of Gut Immune Remodeling by Microbiota and Immune Checkpoint Inhibitor Treatment |
| Funding Source: | NIH |
| Role: | Co-I |
| ID: | FP00027428 |
| Date: | 2026 - 2031 |
| Title: | Defining Cell-intrinsic vs. Cell-extrinsic Mechanisms Driving Protective Anti-tumor Immunity Downstream of PD-1 Checkpoint Inhibition |
| Funding Source: | NIH |
| Role: | Other Significant Contributor |
| ID: | FP00026755 |
| Date: | 2026 - 2031 |
| Title: | Multispectral HyperCEST MRI to Assess Changes in Immune Tumor Microenvironment in Response to Immunotherapy |
| Funding Source: | NIH |
| Role: | Co-I |
| ID: | FP00026033 |
| Date: | 2026 - 2031 |
| Title: | Targeting Macrophage and T Cell Networks to Enhance Cancer Immunotherapy |
| Funding Source: | NCI |
| Role: | Co-I |
| ID: | 1 R01 CA 314062 - 01 |
| Date: | 2026 - Present |
| Title: | Defining How Immune Cell Recruitment Impacts the Transcriptional and Epigenetic Landscape of Pancreatic Islets to Drive Type 1 Diabetes |
| Funding Source: | Breakthrough T1D |
| Role: | Co-I |
| ID: | FP00028465 |
| Date: | 2026 - 2030 |
| Title: | Determining the mechanistic basis for how PD-1 checkpoint modulation promotes productive anti-tumor immunity |
| Funding Source: | American Cancer Society, National (ACS) |
| Role: | Other Significant Contributor |
| ID: | FP00026704 |
| Date: | 2026 - 2029 |
| Title: | Identifying novel immunotherapy targets by interrogating tumor-immune secretomes |
| Funding Source: | Robert J. Kleberg, Jr. and Helen C. Kleberg Foundation |
| Role: | PI |
| ID: | FP00028126 |
| Date: | 2026 - 2028 |
| Title: | Light-Activated Proximity Labeling to Decode and Modulate Glioma-Immune-Neuron Interfaces In Vivo |
| Funding Source: | Damon Runyon Cancer Research Foundation |
| Role: | Collaborator |
| ID: | FP00026486 |
| Date: | 2025 - Present |
| Title: | Decoding and Perturbing Tumor-immune Cell Communication During Lung Cancer Progression |
| Funding Source: | CPRIT |
| Role: | PI |
| ID: | FP00026322 |
| Date: | 2025 - Present |
| Title: | Targeting Peripheral CD8 T cell Migration to Improve Outcomes to PD-1-based Immunotherapy for Cancer |
| Funding Source: | ACS |
| Role: | Co-I |
| ID: | FP00025973 |
| Date: | 2025 - 2030 |
| Title: | Dissecting How Basal and Acute Inflammatory Type I IFNs Control Leukocyte Migration to Lymph Nodes |
| Funding Source: | NIH |
| Role: | PI |
| ID: | FP00025311 |
| Date: | 2025 - 2030 |
| Title: | Rational Design of Nanoantioxidants to Restore T Cell Functionalities for Cancer Immunotherapy |
| Funding Source: | NIH (Subaward via Virginia Tech) |
| Role: | PI |
| ID: | FP00025219 |
| Date: | 2025 - 2028 |
| Title: | Decoding and Perturbing Tumor-immune Cell Communication During Lung Cancer Progression |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | PI |
| ID: | RP 260261 |
| Date: | 2025 - 2028 |
| Title: | Targeting Peripheral CD8 T cell Migration to Improve Outcomes to PD-1-based Immunotherapy for Cancer |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Other Significant Contributor |
| ID: | RP 260157 |
| Date: | 2025 - Present |
| Title: | Disentangling melanoma and immune cell secreted factors to identify new therapeutic vulnerabilities |
| Funding Source: | V Foundation for Cancer Research |
| Role: | PI |
| ID: | FP00027165 |
| Date: | 2025 - Present |
| Title: | Dissecting how tumor and immune cells communicate in lung tumors |
| Funding Source: | Edward Mallinckrodt Jr. Foundation |
| Role: | PI |
| ID: | FP00027373 |
| Date: | 2025 - 2028 |
| Title: | Dissecting How Tumor and Immune Cells Communicate in Lung Tumors |
| Funding Source: | Edward Mallinckrodt, Jr. Foundation |
| Role: | PI |
| ID: | FP00027373 |
| Date: | 2025 - 2028 |
| Title: | Disentangling Melanoma and Immune Cell Secreted Factors to Identify New Therapeutic Vulnerabilities |
| Funding Source: | V Foundation |
| Role: | PI |
| ID: | FP00027165 |
| Date: | 2025 - Present |
| Title: | Identifying Solid Tumor Driven Changes to Hematopoiesis and Circulating Immunity Over Tumor Evolution |
| Funding Source: | American Cancer Society |
| Role: | PI |
| ID: | FP00024446 |
| Date: | 2025 - 2030 |
| Title: | Dissecting Inflammatory and Neuroimmune Mechanisms That Drive Leukocyte Migration Paralysis |
| Funding Source: | NIAID/ NIH |
| Role: | PI |
| ID: | R01AI193165 |
| Date: | 2025 - 2030 |
| Title: | Harnessing Leukocyte Recruitment to Enhance PD-1-based Immunotherapy for Cancer |
| Funding Source: | NCI |
| Role: | Other Significant Contributor |
| ID: | 1 R01 CA 302939 - 01 |
| Date: | 2025 - 2029 |
| Title: | Identifying solid tumor driven changes to hematopoiesis and circulating immunity over tumor evolution |
| Funding Source: | American Cancer Society |
| Role: | PI |
| ID: | FP00024446 |
| Date: | 2025 - 2027 |
| Title: | Defining Hematopoietic Perturbations in Lung Cancer |
| Funding Source: | American Society of Hematology (ASH) |
| Role: | Mentor |
| ID: | FP00025516 |
| Date: | 2025 - 2027 |
| Title: | Engineering Polypeptide-Based mRNA Nanovaccine System for Cancer Immunotherapy |
| Funding Source: | NIH (Subaward via Virginia Tech) |
| Role: | PI |
| ID: | FP00024450 |
| Date: | 2025 - 2026 |
| Title: | Defining Inflammatory Mechanisms Responsible for Leukocyte Migration Paralysis |
| Funding Source: | Sabin Family Fellows Program |
| Role: | PI |
| ID: | RCTS2025-00065040-Y1; Fund: 130092 |
| Date: | 2025 - 2030 |
| Title: | Mechanistic Studies on a Pro-Metastatic Secretory Program in Lung Cancer |
| Funding Source: | NCI |
| Role: | Collaborator |
| ID: | 1 R01 CA298130 - 01 |
| Date: | 2025 - 2030 |
| Title: | Dissecting Hematopoietic and Systemic Immune Perturbations Mediated by Solid-Tumors |
| Funding Source: | NIH |
| Role: | Mentor |
| ID: | FP00023686 |
| Date: | 2022 - 2027 |
| Title: | Identifying the contributions of timing and location in T cell dysfunction in tumors |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Investigator |
| ID: | RR22086 |
| Date: | 2021 - 2026 |
| Title: | The ontogeny and function of CD8 T cells in lung cancer |
| Funding Source: | NIH/NCI |
| Role: | Investigator |
| ID: | K08 CA256044 |
| Date: | 2013 - 2016 |
| Title: | Trafficking & role of effector memory CD8 T cell subsets in small intestine |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | F30 DK100159 |
Selected Publications
Peer-Reviewed Articles
- Zhu, B, Aminu, M, Chen, P, Li, J, Dong, C, Li, C, Tian, Y, Lu, SW, Chen, H, Ma, C, Hu, X, Ye, J, Liu, AY, Huang, B, Rojas, FR, Roger, PE, Shi, O, Nilsson, M, Poteete, A, Khan, KB, Lu, W, Solis Soto, LM, Fujimoto, J, Haymaker, CL, Wistuba, II, Wei, Z, Wang, L, Gibbons, DL, Chen, KS, Reuben, A, Schenkel, JM, Heymach, JV, Cheng, C, Wu, J, Zhang, J. Spatial Profiling Reveals Distinct Molecular and Immune Evolution of Mouse Lung Adenocarcinoma Precancers with or Without Carcinogen Exposure. Advanced Science 13(17), 2026. e-Pub 2026. PMID: 41580978.
- Joag, V, Bimber, BN, Quarnstrom, CF, Bollimpelli, VS, Schenkel, JM, Fraser, KA, Bertogliat, M, Soerens, AG, Stolley, JM, O'Flanagan, SD, Rosato, PC, Gavil, NV, Künzli, M, Mitchell, JS, Legere, T, Jean, S, Upadhyay, AA, Kang, CY, Gibbs, JS, Yewdell, JW, Fife, BT, Park, HS, Hansen, SG, Bosinger, S, Barber, GN, Skinner, PJ, Vezys, V, Hunter, E, Picker, LJ, Amara, RR, Masopust, D. Primate resident memory T cells activate humoral and stromal immunity. Immunity 58(10):2541-2555.e6, 2025. e-Pub 2025. PMID: 41092897.
- Pauken, KE, Markson, SC, Conway, TS, Juneja, VR, Shahid, O, Burke, KP, Rowe, JH, Nguyen, TH, Collier, JL, Walsh, JM, Fung, ME, Luber, JM, Ringel, AE, Schenkel, JM, Freeman, GJ, Haigis, MC, Singer, M, Sharpe, AH. PD-1 regulates tumor-infiltrating CD8+ T cells in both a cell-intrinsic and a cell-extrinsic fashion. The Journal of experimental medicine 222(10), 2025. e-Pub 2025. PMID: 40705010.
- Mahuron, KM, Shahid, O, Sao, P, Wu, C, Haugh, AM, Huppert, LA, Levine, LS, Lowe, MM, Alvarado, M, Micu, M, Tsai, KK, Chow, M, Singer, M, Schenkel, JM, Sharpe, AH, Rosenblum, MD, Pauken, KE, Daud, AI. Single-Cell Analyses Reveal a Functionally Heterogeneous Exhausted CD8+ T-cell Subpopulation That Is Correlated with Response to Checkpoint Therapy in Melanoma. Cancer Research 85(8):1424-1440, 2025. e-Pub 2025. PMID: 40042995.
- Gonta, R, Schenkel, JM, Klein, K, Martinez, F, Medina, MC. Factors influencing white blood cell mobilisation in healthy granulocyte donors. Transfusion Medicine 35(2):177-183, 2025. e-Pub 2025. PMID: 39601217.
- Hagan, NB, Inaku, C, Kunder, NP, White, T, Iraguha, T, Meyer, A, Pauken, KE, Schenkel, JM. In vivo antibody labeling route and fluorophore dictate labeling efficiency, sensitivity, and longevity. Journal of immunology (Baltimore, Md. : 1950) 214(4):828-838, 2025. e-Pub 2025. PMID: 40073090.
- Hagan NB, Inaku C, Kunder N, White T, Iraguha T, Meyer A, Pauken KE, Schenkel JM. In vivo antibody labeling route and fluorophore dictate labeling efficiency, sensitivity, and longevity. bioRxiv, 2024. e-Pub 2024. PMID: 39149319.
- Shanahan SL, Kunder N, Inaku C, Hagan NB, Gibbons G, Mathey-Andrews N, Anandappa G, Soares S, Pauken KE, Jacks T, Schenkel JM. Longitudinal Intravascular Antibody Labeling Identified Regulatory T Cell Recruitment as a Therapeutic Target in a Mouse Model of Lung Cancer. J Immunol 213(6):906-918, 2024. e-Pub 2024. PMID: 39082930.
- Gonta, R, Schenkel, JM, Engel, B, Klein, K, Martinez, F, Knopfelmacher Couchonal, AM, Aung, FM, Correa Medina, M. P-BB-1 | Factors Influencing White Blood Cell (WBC) Mobilization in Healthy Granulocyte Donors. Transfusion 63(S5):90A-91A, 2023. e-Pub 2023.
- Rosato PC, Lotfi-Emran S, Joag V, Wijeyesinghe S, Quarnstrom CF, Degefu HN, Nedellec R, Schenkel JM, Beura LK, Hangartner L, Burton DR, Masopust D. Tissue-resident memory T cells trigger rapid exudation and local antibody accumulation. Mucosal Immunol 16(1):17-26, 2023. e-Pub 2023. PMID: 36657662.
- Naranjo S, Cabana CM, LaFave LM, Romero R, Shanahan SL, Bhutkar A, Westcott PMK, Schenkel JM, Ghosh A, Liao LZ, Del Priore I, Yang D, Jacks T. Modeling diverse genetic subtypes of lung adenocarcinoma with a next-generation alveolar type 2 organoid platform. Genes Dev 36(15-16):936-949, 2022. e-Pub 2022. PMID: 36175034.
- Hwang WL, Jagadeesh KA, Guo JA, Hoffman HI, Yadollahpour P, Reeves JW, Mohan R, Drokhlyansky E, Van Wittenberghe N, Ashenberg O, Farhi SL, Schapiro D, Divakar P, Miller E, Zollinger DR, Eng G, Schenkel JM, Su J, Shiau C, Yu P, Freed-Pastor WA, Abbondanza D, Mehta A, Gould J, Lambden C, Porter CBM, Tsankov A, Dionne D, Waldman J, Cuoco MS, Nguyen L, Delorey T, Phillips D, Barth JL, Kem M, Rodrigues C, Ciprani D, Roldan J, Zelga P, Jorgji V, Chen JH, Ely Z, Zhao D, Fuhrman K, Fropf R, Beechem JM, Loeffler JS, Ryan DP, Weekes CD, Ferrone CR, Qadan M, Aryee MJ, Jain RK, Neuberg DS, Wo JY, Hong TS, Xavier R, Aguirre AJ, Rozenblatt-Rosen O, Mino-Kenudson M, Castillo CF, Liss AS, Ting DT, Jacks T, Regev A. Single-nucleus and spatial transcriptome profiling of pancreatic cancer identifies multicellular dynamics associated with neoadjuvant treatment. Nat Genet 54(8):1178-1191, 2022. e-Pub 2022. PMID: 35902743.
- Jaeger AM, Stopfer LE, Ahn R, Sanders EA, Sandel DA, Freed-Pastor WA, Rideout WM, Naranjo S, Fessenden T, Nguyen KB, Winter PS, Kohn RE, Westcott PMK, Schenkel JM, Shanahan SL, Shalek AK, Spranger S, White FM, Jacks T. Deciphering the immunopeptidome in vivo reveals new tumour antigens. Nature 607(7917):149-155, 2022. e-Pub 2022. PMID: 35705813.
- Schenkel JM, Herbst RH, Canner D, Li A, Hillman M, Shanahan SL, Gibbons G, Smith OC, Kim JY, Westcott P, Hwang WL, Freed-Pastor WA, Eng G, Cuoco MS, Rogers P, Park JK, Burger ML, Rozenblatt-Rosen O, Cong L, Pauken KE, Regev A, Jacks T. Conventional type I dendritic cells maintain a reservoir of proliferative tumor-antigen specific TCF-1+ CD8+ T cells in tumor-draining lymph nodes. Immunity 54(10):2338-2353.e6, 2021. e-Pub 2021. PMID: 34534439.
- Freed-Pastor WA, Lambert LJ, Ely ZA, Pattada NB, Bhutkar A, Eng G, Mercer KL, Garcia AP, Lin L, Rideout WM, Hwang WL, Schenkel JM, Jaeger AM, Bronson RT, Westcott PMK, Hether TD, Divakar P, Reeves JW, Deshpande V, Delorey T, Phillips D, Yilmaz OH, Regev A, Jacks T. The CD155/TIGIT axis promotes and maintains immune evasion in neoantigen-expressing pancreatic cancer. Cancer Cell 39(10):1342-1360.e14, 2021. e-Pub 2021. PMID: 34358448.
- Westcott PMK, Sacks NJ, Schenkel JM, Ely ZA, Smith O, Hauck H, Jaeger AM, Zhang D, Backlund CM, Beytagh MC, Patten JJ, Elbashir R, Eng G, Irvine DJ, Yilmaz OH, Jacks T. Low neoantigen expression and poor T-cell priming underlie early immune escape in colorectal cancer. Nature Cancer 2(10):1071-1085, 2021. e-Pub 2021. PMID: 34738089.
- Burger ML, Cruz AM, Crossland GE, Gaglia G, Ritch CC, Blatt SE, Bhutkar A, Canner D, Kienka T, Tavana SZ, Barandiaran AL, Garmilla A, Schenkel JM, Hillman M, de Los Rios Kobara I, Li A, Jaeger AM, Hwang WL, Westcott PMK, Manos MP, Holovatska MM, Hodi FS, Regev A, Santagata S, Jacks T. Antigen dominance hierarchies shape TCF1+ progenitor CD8 T cell phenotypes in tumors. Cell 184(19):4996-5014.e26, 2021. e-Pub 2021. PMID: 34534464.
- Pauken KE, Shahid O, Lagattuta KA, Mahuron KM, Luber JM, Lowe MM, Huang L, Delaney C, Long JM, Fung ME, Newcomer K, Tsai KK, Chow M, Guinn S, Kuchroo JR, Burke KP, Schenkel JM, Rosenblum MD, Daud AI, Sharpe AH, Singer M. Single-cell analyses identify circulating anti-tumor CD8 T cells and markers for their enrichment. Journal Experimental Medicine 218(4), 2021. e-Pub 2021. PMID: 33651880.
- Johnnidis JB, Muroyama Y, Ngiow SF, Chen Z, Manne S, Cai Z, Song S, Platt JM, Schenkel JM, Abdel-Hakeem M, Beltra JC, Greenplate AR, Ali MA, Nzingha K, Giles JR, Harly C, Attanasio J, Pauken KE, Bengsch B, Paley MA, Tomov VT, Kurachi M, Vignali DAA, Sharpe AH, Reiner SL, Bhandoola A, Johnson FB, Wherry EJ. Inhibitory signaling sustains a distinct early memory CD8+ T cell precursor that is resistant to DNA damage. Science Immunology 6(55), 2021. e-Pub 2021. PMID: 33452106.
- Newman JH, Chesson CB, Herzog NL, Bommareddy PK, Aspromonte SM, Pepe R, Estupinian R, Aboelatta MM, Buddhadev S, Tarabichi S, Lee M, Li S, Medina DJ, Giurini EF, Gupta KH, Guevara-Aleman G, Rossi M, Nowicki C, Abed A, Goldufsky JW, Broucek JR, Redondo RE, Rotter D, Jhawar SR, Wang SJ, Kohlhapp FJ, Kaufman HL, Thomas PG, Gupta V, Kuzel TM, Reiser J, Paras J, Kane MP, Singer EA, Malhotra J, Denzin LK, Sant'Angelo DB, Rabson AB, Lee LY, Lasfar A, Langenfeld J, Schenkel JM, Fidler MJ, Ruiz ES, Marzo AL, Rudra JS, Silk AW, Zloza A. Intratumoral injection of the seasonal flu shot converts immunologically cold tumors to hot and serves as an immunotherapy for cancer. Proc Natl Acad Sci U S A 117(2):1119-1128, 2020. e-Pub 2020. PMID: 31888983.
- Ng SR, Rideout WM, Akama-Garren EH, Bhutkar A, Mercer KL, Schenkel JM, Bronson RT, Jacks T. CRISPR-mediated modeling and functional validation of candidate tumor suppressor genes in small cell lung cancer. Proc Natl Acad Sci U S A 117(1):513-521, 2020. e-Pub 2020. PMID: 31871154.
- Li A, Herbst RH, Canner D, Schenkel JM, Smith OC, Kim JY, Hillman M, Bhutkar A, Cuoco MS, Rappazzo CG, Rogers P, Dang C, Jerby-Arnon L, Rozenblatt-Rosen O, Cong L, Birnbaum M, Regev A, Jacks T. IL-33 Signaling Alters Regulatory T Cell Diversity in Support of Tumor Development. Cell Reports 29(10):2998-3008.e8, 2019. e-Pub 2019. PMID: 31801068.
- Beura LK, Fares-Frederickson NJ, Steinert EM, Scott MC, Thompson EA, Fraser KA, Schenkel JM, Vezys V, Masopust D. CD4+ resident memory T cells dominate immunosurveillance and orchestrate local recall responses. J Exp Med 216(5):1214-1229, 2019. e-Pub 2019. PMID: 30923043.
- Schenkel JM, Hergott CB, Dudley G, Drew M, Charest K, Dorfman DM. Use of a Blast Dominance-Hematogone Index for the Flow Cytometric Evaluation of Myelodysplastic Syndrome (MDS). Am J Clin Pathol 151(6):584-592, 2019. e-Pub 2019. PMID: 30854558.
- Romaguera JE, Lee HJ, Tarapore R, Prabhu V, Allen J, Schalop L, Zloza A, Ok CY, Sadimin ET, Schenkel J, Badillo M, Wang M. Integrated stress response and immune cell infiltration in an ibrutinib-refractory mantle cell lymphoma patient following ONC201 treatment. Br J Haematol 185(1):133-136, 2019. e-Pub 2019. PMID: 29740811.
- Gansner JM, Rahmani M, Jonsson AH, Fortin BM, Brimah I, Ellis M, Smeland-Wagman R, Li ZJ, Schenkel JM, Brenner MB, Yefidoff-Freedman R, Sloan SR, Berliner N, Issa NC, Baden LR, Longo DL, Wesemann DR, Neuberg D, Rao DA, Kaufman RM. Plateletpheresis-associated lymphopenia in frequent platelet donors. Blood 133(6):605-614, 2019. e-Pub 2019. PMID: 30429159.
- Mehnert JM, Silk AW, Lee JH, Dudek L, Jeong BS, Li J, Schenkel JM, Sadimin E, Kane M, Lin H, Shih WJ, Zloza A, Chen S, Goydos JS. A phase II trial of riluzole, an antagonist of metabotropic glutamate receptor 1 (GRM1) signaling, in patients with advanced melanoma. Pigment Cell Melanoma Res 31(4):534-540, 2018. e-Pub 2018. PMID: 29453787.
- Beura LK, Wijeyesinghe S, Thompson EA, Macchietto MG, Rosato PC, Pierson MJ, Schenkel JM, Mitchell JS, Vezys V, Fife BT, Shen S, Masopust D. T Cells in Nonlymphoid Tissues Give Rise to Lymph-Node-Resident Memory T Cells. Immunity 48(2):327-338.e5, 2018. e-Pub 2018. PMID: 29466758.
- Beura LK, Mitchell JS, Thompson EA, Schenkel JM, Mohammed J, Wijeyesinghe S, Fonseca R, Burbach BJ, Hickman HD, Vezys V, Fife BT, Masopust D. Intravital mucosal imaging of CD8+ resident memory T cells shows tissue-autonomous recall responses that amplify secondary memory. Nature Immunology 19(2):173-182, 2018. e-Pub 2018. PMID: 29311694.
- Huang AC, Postow MA, Orlowski RJ, Mick R, Bengsch B, Manne S, Xu W, Harmon S, Giles JR, Wenz B, Adamow M, Kuk D, Panageas KS, Carrera C, Wong P, Quagliarello F, Wubbenhorst B, D'Andrea K, Pauken KE, Herati RS, Staupe RP, Schenkel JM, McGettigan S, Kothari S, George SM, Vonderheide RH, Amaravadi RK, Karakousis GC, Schuchter LM, Xu X, Nathanson KL, Wolchok JD, Gangadhar TC, Wherry EJ. T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature 545(7652):60-65, 2017. e-Pub 2017. PMID: 28397821.
- Pauken KE, Sammons MA, Odorizzi PM, Manne S, Godec J, Khan O, Drake AM, Chen Z, Sen DR, Kurachi M, Barnitz RA, Bartman C, Bengsch B, Huang AC, Schenkel JM, Vahedi G, Haining WN, Berger SL, Wherry EJ. Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade. Science 354(6316):1160-1165, 2016. e-Pub 2016. PMID: 27789795.
- Kohlhapp FJ, Huelsmann EJ, Lacek AT, Schenkel JM, Lusciks J, Broucek JR, Goldufsky JW, Hughes T, Zayas JP, Dolubizno H, Sowell RT, Kühner R, Burd S, Kubasiak JC, Nabatiyan A, Marshall S, Bommareddy PK, Li S, Newman JH, Monken CE, Shafikhani SH, Marzo AL, Guevara-Patino JA, Lasfar A, Thomas PG, Lattime EC, Kaufman HL, Zloza A. Non-oncogenic Acute Viral Infections Disrupt Anti-cancer Responses and Lead to Accelerated Cancer-Specific Host Death. Cell Rep 17(4):957-965, 2016. e-Pub 2016. PMID: 27760326.
- Manlove LS, Schenkel JM, Manlove KR, Pauken KE, Williams RT, Vezys V, Farrar MA. Heterologous Vaccination and Checkpoint Blockade Synergize To Induce Antileukemia Immunity. Journal of Immunology 196(11):4793-804, 2016. e-Pub 2016. PMID: 27183622.
- Schenkel JM, Fraser KA, Casey KA, Beura LK, Pauken KE, Vezys V, Masopust D. IL-15-Independent Maintenance of Tissue-Resident and Boosted Effector Memory CD8 T Cells. J Immunol 196(9):3920-6, 2016. e-Pub 2016. PMID: 27001957.
- Beura LK, Hamilton SE, Bi K, Schenkel JM, Odumade OA, Casey KA, Thompson EA, Fraser KA, Rosato PC, Filali-Mouhim A, Sekaly RP, Jenkins MK, Vezys V, Haining WN, Jameson SC, Masopust D. Normalizing the environment recapitulates adult human immune traits in laboratory mice. Nature 532(7600):512-6, 2016. e-Pub 2016. PMID: 27096360.
- Hondowicz BD, An D, Schenkel JM, Kim KS, Steach HR, Krishnamurty AT, Keitany GJ, Garza EN, Fraser KA, Moon JJ, Altemeier WA, Masopust D, Pepper M. Interleukin-2-Dependent Allergen-Specific Tissue-Resident Memory Cells Drive Asthma. Immunity 44(1):155-166, 2016. e-Pub 2016. PMID: 26750312.
- Steinert EM, Schenkel JM, Fraser KA, Beura LK, Manlove LS, Igyártó BZ, Southern PJ, Masopust D. Quantifying Memory CD8 T Cells Reveals Regionalization of Immunosurveillance. Cell 161(4):737-49, 2015. e-Pub 2015. PMID: 25957682.
- Pauken KE, Nelson CE, Martinov T, Spanier JA, Heffernan JR, Sahli NL, Quarnstrom CF, Osum KC, Schenkel JM, Jenkins MK, Blazar BR, Vezys V, Fife BT. Cutting edge: identification of autoreactive CD4+ and CD8+ T cell subsets resistant to PD-1 pathway blockade. J Immunol 194(8):3551-3555, 2015. e-Pub 2015. PMID: 25769925.
- Beura LK, Anderson KG, Schenkel JM, Locquiao JJ, Fraser KA, Vezys V, Pepper M, Masopust D. Lymphocytic choriomeningitis virus persistence promotes effector-like memory differentiation and enhances mucosal T cell distribution. Journal of Leukocyte Biology 97(2):217-25, 2015. e-Pub 2015. PMID: 25395301.
- Kohlhapp FJ, Broucek JR, Hughes T, Huelsmann EJ, Lusciks J, Zayas JP, Dolubizno H, Fleetwood VA, Grin A, Hill GE, Poshepny JL, Nabatiyan A, Ruby CE, Snook JD, Rudra JS, Schenkel JM, Masopust D, Zloza A, Kaufman HL. NK cells and CD8+ T cells cooperate to improve therapeutic responses in melanoma treated with interleukin-2 (IL-2) and CTLA-4 blockade. Journal for Immunotherapy of Cancer 3:18, 2015. e-Pub 2015. PMID: 25992289.
- Zloza A, Kim DW, Broucek J, Schenkel JM, Kaufman HL. High-dose IL-2 induces rapid albumin uptake by endothelial cells through Src-dependent caveolae-mediated endocytosis. Journal Interferon & Cytokine Research 34(11):915-9, 2014. e-Pub 2014. PMID: 24963699.
- Schenkel JM, Fraser KA, Beura LK, Pauken KE, Vezys V, Masopust D. T cell memory. Resident memory CD8 T cells trigger protective innate and adaptive immune responses. Science 346(6205):98-101, 2014. e-Pub 2014. PMID: 25170049.
- Mahmud SA, Manlove LS, Schmitz HM, Xing Y, Wang Y, Owen DL, Schenkel JM, Boomer JS, Green JM, Yagita H, Chi H, Hogquist KA, Farrar MA. Costimulation via the tumor-necrosis factor receptor superfamily couples TCR signal strength to the thymic differentiation of regulatory T cells. Nature Immunology 15(5):473-81, 2014. e-Pub 2014. PMID: 24633226.
- Kim DW, Zloza A, Broucek J, Schenkel JM, Ruby C, Samaha G, Kaufman HL. Interleukin-2 alters distribution of CD144 (VE-cadherin) in endothelial cells. Journal of Translational Medicine 12:113, 2014. e-Pub 2014. PMID: 24885155.
- Schenkel JM, Fraser KA, Masopust D. Cutting edge: resident memory CD8 T cells occupy frontline niches in secondary lymphoid organs. Journal of Immunology 192(7):2961-4, 2014. e-Pub 2014. PMID: 24600038.
- Sakai S, Kauffman KD, Schenkel JM, McBerry CC, Mayer-Barber KD, Masopust D, Barber DL. Cutting edge: control of Mycobacterium tuberculosis infection by a subset of lung parenchyma-homing CD4 T cells. Journal of Immunology 192(7):2965-9, 2014. e-Pub 2014. PMID: 24591367.
- Schenkel JM, Masopust D. Identification of a resident T-cell memory core transcriptional signature. Immunology and Cell Biology 92(1):8-9, 2014. e-Pub 2014. PMID: 24165982.
- Fraser KA, Schenkel JM, Jameson SC, Vezys V, Masopust D. Preexisting high frequencies of memory CD8+ T cells favor rapid memory differentiation and preservation of proliferative potential upon boosting. Immunity 39(1):171-83, 2013. e-Pub 2013. PMID: 23890070.
- Schenkel JM, Fraser KA, Vezys V, Masopust D. Sensing and alarm function of resident memory CD8? T cells. Nature Immunology 14(5):509-13, 2013. e-Pub 2013. PMID: 23542740.
- Casey KA, Fraser KA, Schenkel JM, Moran A, Abt MC, Beura LK, Lucas PJ, Artis D, Wherry EJ, Hogquist K, Vezys V, Masopust D. Antigen-independent differentiation and maintenance of effector-like resident memory T cells in tissues. Journal Immunology 188(10):4866-75, 2012. e-Pub 2012. PMID: 22504644.
- Zloza A, Kohlhapp FJ, Lyons GE, Schenkel JM, Moore TV, Lacek AT, O'Sullivan JA, Varanasi V, Williams JW, Jagoda MC, Bellavance EC, Marzo AL, Thomas PG, Zafirova B, Polic B, Al-Harthi L, Sperling AI, Guevara-Patiño JA. NKG2D signaling on CD8? T cells represses T-bet and rescues CD4-unhelped CD8? T cell memory recall but not effector responses. Nature Medicine 18(3):422-8, 2012. e-Pub 2012. PMID: 22366950.
- Hamilton SE, Schenkel JM, Akue AD, Jameson SC. IL-2 complex treatment can protect naive mice from bacterial and viral infection. Journal of Immunology 185(11):6584-90, 2010. e-Pub 2010. PMID: 21037095.
- Schenkel JM, Zloza A, Li W, Narasipura SD, Al-Harthi L. Beta-catenin signaling mediates CD4 expression on mature CD8+ T cells. Journal of Immunology 185(4):2013-9, 2010. e-Pub 2010. PMID: 20631314.
- Zloza A, Schenkel JM, Tenorio AR, Martinson JA, Jeziorczak PM, Al-Harthi L. Potent HIV-specific responses are enriched in a unique subset of CD8+ T cells that coexpresses CD4 on its surface. Blood 114(18):3841-53, 2009. e-Pub 2009. PMID: 19700667.
Review Articles
- Schenkel JM. Localization, tissue biology and T cell state — implications for cancer immunotherapy. Nat Rev Immunol 23(12):807-823, 2023. e-Pub 2023. PMID: 37253877.
- Shi DD, Guo JA, Hoffman HI, Su J, Mino-Kenudson M, Barth JL, Schenkel JM, Loeffler JS, Shih HA, Hong TS, Wo JY, Aguirre AJ, Jacks T, Zheng L, Wen PY, Wang TC, Hwang WL. Therapeutic avenues for cancer neuroscience: translational frontiers and clinical opportunities. Lancet Oncol 23(2):e62-e74, 2022. e-Pub 2022. PMID: 35114133.
- Jhawar SR, Thandoni A, Bommareddy PK, Hassan S, Kohlhapp FJ, Goyal S, Schenkel JM, Silk AW, Zloza A. Oncolytic Viruses-Natural and Genetically Engineered Cancer Immunotherapies. Frontiers in Oncology 7:202, 2017. e-Pub 2017. PMID: 28955655.
- Schenkel JM, Masopust D. Tissue-resident memory T cells. Immunity 41(6):886-97, 2014. e-Pub 2014. PMID: 25526304.
- Masopust D, Schenkel JM. The integration of T cell migration, differentiation and function. Nature Reviews Immunology 13(5):309-20, 2013. e-Pub 2013. PMID: 23598650.
Patient Reviews
CV information above last modified July 22, 2026